The drug helped patients reduce their weight by only 22.7 per cent, falling short of the anticipated result. Novo’s shares ...

Around the holidays – when many people are baking cookies for Santa, enjoying cocktail parties or having festive family feasts – some adults who use popular medications for diabetes or weight loss ...

Former FDA Commissioner Dr. Scot Gottlieb joins 'Squawk Box' to discuss the future of pharmaceutical advertising, health care ...

Weight-loss drugs such as semaglutide are increasingly popular among adults, who have flocked to the new medication as an ...

The U.S. Food and Drug Administration on Friday approved the first prescription medicine for obstructive sleep apnea: the ...

Novo Nordisk's shares recovered some ground on Monday after a 27% slump on Friday in response to an underwhelming set of results from a Phase III trial of its new weight-loss drug CagriSema, but ...

The statistics continue to be alarming, with no indication that the global rise in obesity is slowing. The real question ...

Elected officials are looking to expand access to weight loss drugs like Ozempic and Wegovy for low-income Virginians as part ...

In a recent head-to-head study involving Novo Nordisk 's Wegovy, Zepbound came out on top, resulting in average weight loss ...

Novo Nordisk shares have plunged 20% amid the disappointing trial result of its latest weight-loss drug CagriSema. The fall ...

Already established as cornerstone therapies in diabetes and obesity, GLP-1 receptor agonists have now cracked into the ...

Zepbound, a popular weight loss drug, has become the first FDA-approved prescription medication to treat obstructive sleep ...